Scancell’s iSCIB1+ Shows Promising Results in Melanoma Treatment

The latest update is out from Scancell Holdings ( (GB:SCLP) ).

Scancell Holdings announced positive Phase 2 trial results for their iSCIB1+ Immunobody® DNA active immunotherapy in treating late-stage melanoma, presented at the SITC 2025 meeting. The trial showed a progression-free survival rate of 78% at 11 months, significantly higher than the historical 46% with existing therapies, positioning iSCIB1+ as a transformative treatment option. The company plans to accelerate development, including regulatory discussions and randomized studies set to begin in 2026, potentially expanding treatment to 80% of late-stage melanoma patients.

Spark’s Take on GB:SCLP Stock

According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.

Scancell Holdings’ overall stock score is heavily influenced by its poor financial performance, characterized by zero revenue and significant losses. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.

To see Spark’s full report on GB:SCLP stock, click here.

More about Scancell Holdings

Scancell Holdings plc is a clinical-stage biotechnology company focused on developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumor-specific immunity. Their lead product from the DNA ImmunoBody® platform, iSCIB1+, has shown significant benefits in treating melanoma, and they are also developing peptide immunotherapies and high-affinity antibodies through their subsidiary, GlyMab Therapeutics Ltd.

Average Trading Volume: 920,317

Technical Sentiment Signal: Sell

Current Market Cap: £102.2M

Learn more about SCLP stock on TipRanks’ Stock Analysis page.